Member Info for Riesgo

Could it be an invitation to receive a brief on everything up-to the early Jan RNS?
An excellent story to tell with plenty of promise for the future of cancer treatment.

Lol. 17/01/23 when the Gin wears off.

Kev, what else are you expecting?
19/12/22 RNS said
‘The Company will update the Market on progress in this study in early January 2023, in advance of the Science Day’.
The 17/01/12 RNS was not long after early Jan and some say it counts as early Jan..

Surely if AS has simple and clear price sensitive data as suggested we would know already.
Maybe it’s not that simple or clear yet.

I agree Mowzer. I imagine AVA6k being like accurate carpet bombing. No time for cells to build up resistance. Just wish Avacta would address this.

I’ve recently read that cancer cells eventually resist attack by Dox. Anyone know if AVA6k slows this down? I don’t recall any Avacta information on this.

Wait if you think it is best for you. But it looks more likely the SP will increase as we approach Science Day, especially after Friday’s late large buys.

Thanks for posting this Bet. Can’t say I understand it all, but a couple of thoughts came to mind.
1. Is it competition or compatible with AVA6k?
2. Chemotoxin resistance of cancer cells to Dox is mentioned in addition to its other side effects. So I wonder if AVA6k also reduces chemotoxin resistance of cancer cells. I can’t recall this being mentioned but it would be good if it does and some numbers attributed to it.

Mowzer, perhaps we should not consider ‘therapeutic’ until we know how much better it is. Some data.
As for the LFT the Mologic antibodies did come to mind when I first heard about pulling the LFTs. But I have a box of useless Avacta LFTs in my junk cupboard that were sold to me months earlier on the basis of using Avacta’s marvellous Affimer. There was no mention of antibodies. Event timing can confuse the best.

That’s No 1 on my list. Thanks for helping.

Buena, thought you said you were going to filter me ages ago.

Mowzer, The big let down for me with the LFT was when we were told the wrong antibody was being used! When I thought it was using Affimers.

Mowzer, agree it sounds great and is why I’m still invested. But I do have some nagging doubts when thinking back to the LFT glory days. I ask myself why is Avacta so shy with its price sensitive data? Why are they keeping it back from us? As Tim says, AS must be basing his words on data.

Hope it’s more than made up words.

Not a good point Tim because AS appears to have history with made up words.

On the plus side and probably the reason I think it’s still a good bet, even at the same therapeutic levels as plain Dox the January RNS says AVA6k is a good improvement. So should sell like crazy.

“AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed”

Rooba = No 2 - financial skullduggery.

Presumably, existing levels are therapeutic. So what?

It reminds me of the Remain v Leave debate and I wonder if all arguments have similar traits. It seems that when exhausted of rational argument they use three lines of attack, either directly or implied.
1. They are thick and so do not understand.
2. They are motivated by financial skullduggery.
3. Abuse.
Check it out.

Researchers like to research.